Skip to main content

Hacksaw Ridge



Diane and I have seen the Mel Gibson directed war movie Hacksaw Ridge. The photo here isn't a still from the movie (which doesn't use b-and-w cinematography). No, what I've pasted above is a historic (May 1945) photo of an escarpment on Okinawa that got the nickname that in turn became the title.

The movie hardly needs any recommendation from me. It has been out for weeks already (it opened Nov. 4 in the US) and has received rave reviews.

Rolling Stone calls it the best war movie since Saving Private Ryan, and that periodical's reviewer says that Gibson as director "deserves a medal."

Another reason the movie needs no recommendation from me: it has done quite well already in box-office terms. It made $15.2 million on its opening weekend, $10.8 million on the second.

These aren't blockbuster level numbers. Andrew Garfield, who plays the conscientious objector at the heart of the story, also played Spider-Man in a 2012 movie, and THAT film earned $35 million on its first day. Still, Garfield is reportedly gratified that he has moved into the realm of real world heroes. And the numbers are quite respectable for an early November release, when the studios are saving their biggest guns for the Thanksgiving-to-New-Year run.

With all that, as I say, I don't do anyone associated with the film any favors by recommending this movie.

 Still: here it is. I highly recommend this movie. It will move you. You may not understand Doss' religious principles before or after you see the movie. He was not drafted -- he enlisted. And as that fact suggests he did not object to the war effort. He just wanted his part in it to be purely that of a medic, and of one who would handle no rifle.

Still, heroism doesn't consist in having the right convictions, it consists in having the courage of the convictions one has. And this movie strikes that note well.


Comments

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…